Overview
- In an open-label Phase 2 trial of 19 multiple myeloma patients undergoing autologous transplant, 17 collected at least 2×10^6 CD34+ cells/kg within two leukapheresis sessions and the remaining two reached the target after an additional session.
- Peripheral CD34+ counts peaked within one hour of dosing, supporting potential same-day administration and apheresis.
- Performance remained strong in harder-to-mobilize patients, as 14 of 16 participants with prior daratumumab exposure met the primary endpoint, with higher yields observed when more time had elapsed since the last daratumumab dose.
- The regimen of burixafor plus propranolol and G-CSF showed no burixafor-related adverse events above Grade 2, and among those transplanted the median times to neutrophil and platelet engraftment were 13 and 17.5 days.
- Following the ASH presentation, Exicure shares jumped roughly 140% after-hours and continued higher Tuesday as the company highlights Phase 3 planning and potential extensions to sickle cell disease, cell and gene therapy support, and a planned AML chemosensitization study.